The Technical Analyst
Select Language :
Connect Biopharma [CNTB]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Connect Biopharma Price, Forecast, Insider, Ratings, Fundamentals & Signals

Connect Biopharma is listed at the  Exchange

8.07% $1.740

America/New_York / 28 mar 2024 @ 16:00


Connect Biopharma: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 95.82 mill
EPS: -1.540
P/E: -1.130
Earnings Date: Apr 15, 2024
SharesOutstanding: 55.07 mill
Avg Daily Volume: 0.132 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Sell
P/E: Strong Sell
Price To Book: Neutral
QUARTER GROWTHS
4/212/223/224/221/232/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebitn/an/an/an/an/an/a
Asset n/an/a
Debtn/an/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -1.130 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.19x
Company: PE -1.130 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$1.378
(-20.79%) $-0.362
Date: 2024-03-28
Expected Trading Range (DAY)

$ 1.605 - 1.895

( +/- 8.29%)
ATR Model: 14 days

Forecast: 16:00 - $1.740

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $1.740
Forecast 2: 16:00 - $1.740
Forecast 3: 16:00 - $1.740
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $1.740 (8.07% )
Volume 0.470 mill
Avg. Vol. 0.132 mill
% of Avg. Vol 356.27 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Connect Biopharma Holdings Limited

Last 12 Months

Last 12 months chart data with high, low, open and close for Connect Biopharma Holdings Limited

RSI

Intraday RSI14 chart for Connect Biopharma Holdings Limited

Last 10 Buy & Sell Signals For CNTB

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Connect Biopharma Holdings Limited

CNTB

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Last 10 Buy Signals

Date Signal @
BTGUSDMar 28 - 19:36$49.83
STXUSDMar 28 - 19:35$3.44
INJUSDMar 28 - 19:3438.22
EGXUSDMar 28 - 19:30200.44
WBTCUSDMar 28 - 19:3269 625
KP3RUSDMar 28 - 19:3298.54
LEOUSDMar 28 - 19:286.05
AGIXUSDMar 28 - 19:291.395
STRAXUSDMar 28 - 19:25$0.145
RSS3USDMar 28 - 19:220.561

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.